Cargando…
Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and anti...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451955/ https://www.ncbi.nlm.nih.gov/pubmed/37627705 http://dx.doi.org/10.3390/antibiotics12081285 |
_version_ | 1785095547196014592 |
---|---|
author | Ficik, Jozef Andrezál, Michal Drahovská, Hana Böhmer, Miroslav Szemes, Tomáš Liptáková, Adriána Slobodníková, Lívia |
author_facet | Ficik, Jozef Andrezál, Michal Drahovská, Hana Böhmer, Miroslav Szemes, Tomáš Liptáková, Adriána Slobodníková, Lívia |
author_sort | Ficik, Jozef |
collection | PubMed |
description | The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and antimicrobial resistance globally and locally is vitally important. In a retrospective study, the incidence of CRKP in the pre-COVID-19 period (2017–2019) and the COVID-19 pandemic (2020–2022) was investigated in the Central Military Hospital in Ružomberok, Slovak Republic. The relative incidence of CRKP significantly increased during the COVID-19 period—by 4.8 times, from 0.18 to 0.76%. At the same time, 47% of CRKP-positive patients also had COVID-19. Twenty-six KPC and sixty-nine NDM-producing isolates were identified. CRKPs isolated in the year 2022 were submitted to whole genome sequencing, and their susceptibility was tested to cefiderocol, ceftazidime–avibactam, imipenem–relebactam and meropenem–vaborbactam, with excellent results. KPC-producing isolates were also highly susceptible to colistin (92%). The NDM isolates revealed lower susceptibility rates, including only 57% colistin susceptibility. ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions. |
format | Online Article Text |
id | pubmed-10451955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104519552023-08-26 Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions Ficik, Jozef Andrezál, Michal Drahovská, Hana Böhmer, Miroslav Szemes, Tomáš Liptáková, Adriána Slobodníková, Lívia Antibiotics (Basel) Article The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and antimicrobial resistance globally and locally is vitally important. In a retrospective study, the incidence of CRKP in the pre-COVID-19 period (2017–2019) and the COVID-19 pandemic (2020–2022) was investigated in the Central Military Hospital in Ružomberok, Slovak Republic. The relative incidence of CRKP significantly increased during the COVID-19 period—by 4.8 times, from 0.18 to 0.76%. At the same time, 47% of CRKP-positive patients also had COVID-19. Twenty-six KPC and sixty-nine NDM-producing isolates were identified. CRKPs isolated in the year 2022 were submitted to whole genome sequencing, and their susceptibility was tested to cefiderocol, ceftazidime–avibactam, imipenem–relebactam and meropenem–vaborbactam, with excellent results. KPC-producing isolates were also highly susceptible to colistin (92%). The NDM isolates revealed lower susceptibility rates, including only 57% colistin susceptibility. ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions. MDPI 2023-08-04 /pmc/articles/PMC10451955/ /pubmed/37627705 http://dx.doi.org/10.3390/antibiotics12081285 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ficik, Jozef Andrezál, Michal Drahovská, Hana Böhmer, Miroslav Szemes, Tomáš Liptáková, Adriána Slobodníková, Lívia Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title | Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title_full | Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title_fullStr | Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title_full_unstemmed | Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title_short | Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions |
title_sort | carbapenem-resistant klebsiella pneumoniae in covid-19 era—challenges and solutions |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451955/ https://www.ncbi.nlm.nih.gov/pubmed/37627705 http://dx.doi.org/10.3390/antibiotics12081285 |
work_keys_str_mv | AT ficikjozef carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT andrezalmichal carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT drahovskahana carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT bohmermiroslav carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT szemestomas carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT liptakovaadriana carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions AT slobodnikovalivia carbapenemresistantklebsiellapneumoniaeincovid19erachallengesandsolutions |